Gabapentin as Preanesthetic Medication to Fast Procedures in Pediatric´s Oncology

H

Hospital Infantil Albert Sabin

Status and phase

Completed
Phase 4

Conditions

Vomiting
Agitation States as Acute Reaction to Exceptional Stress
Pain, Postoperative
Anesthesia

Treatments

Drug: GABA 15mg/kg Group
Drug: Placebo Group
Drug: GABA 30mg/kg Group

Study type

Interventional

Funder types

Other

Identifiers

NCT03681574
HOSPITALIAS2

Details and patient eligibility

About

This study is a clinical trial, prospective, randomized and double-blinded. Placebo, Gabapentin syrup at 15 mg/kg, and Gabapentin syrup at 30 mg/kg were administered to reduce agitation before and after in children submitted procedures (myelogram or lumbar puncture) among 1 and 6 years.

Full description

Gabapentin syrup at 15 mg/kg and at 30 mg/kg was administered to reduce the agitation before and after oncologic procedures (myelogram or lumbar puncture) in children among 1 and 6 years. Three groups were compared: the control group received placebo, the other two groups received gabapentin at 15mg/kg or at 30mg/kg. All patients received the same protocols (anesthesia and analgesia). Anesthesia protocol used was induction with sevoflurane 8% plus N2O 50% and oxygen, maintenance with sevoflurane 4%. We provided local analgesia with 5% lidocaine creme before the procedure. If it was required, dipyrone 10mg/kg every 6 hours was given as rescue analgesia. To prevent post-operative vomit, ondasentron 0,1mg/kg was administered when intrathecal chemotherapy. The mYPAS scale was used to evaluate preoperative anxiety at several moments: at basal, at after 1-hour administration, at separation from parents, and at induction. The PAED scale was applied after 30 minutes of procedure to evaluate postoperative agitation. The CHIPPS scale was used to assess postoperative pain. The frequency of vomits was recorded for 8 hours after the procedure finished.

Enrollment

135 patients

Sex

All

Ages

1 to 6 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Cancer or under investigation for cancer.
  • Children between 1 and 6 years.
  • Previously submitted to oncologic procedures, e.g. myelogram or puncture lumbar.

Exclusion criteria

  • Cardiac disease.
  • Pulmonary disease.
  • Renal disease.
  • Neurological disease.
  • Any allergies.
  • Refusal of parents, caregivers or patients to participate in the study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

135 participants in 3 patient groups

Placebo Group
Experimental group
Description:
The placebo group will receive placebo concentrate orally (0.3 mL/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
Treatment:
Drug: Placebo Group
GABA 15mg/kg Group
Experimental group
Description:
The GABA 15mg/kg group will receive gabapentin syrup orally (15 mg/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
Treatment:
Drug: GABA 15mg/kg Group
GABA 30mg/kg Group
Experimental group
Description:
The GABA 30mg/kg group will receive gabapentin syrup orally (30 mg/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
Treatment:
Drug: GABA 30mg/kg Group

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems